Cempra, Inc.CEMP announced positive top line results from a global, phase III study (Solitaire IV) on pipeline candidate intravenous (IV) to oral solithromycin. Cempra is evaluating solithromycin for the treatment of community acquired bacterial pneumonia (CABP). In the study,
Cempra Antibiotic Meets Endpoints, Adverse Events Concerning
